Dr. Bose shares his vision for the future management of patients with intermediate myelofibrosis, including the unmet needs with current treatment options and the emerging data he is closely following.
Case: Intermediate-Risk Primary Myelofibrosis in a 68-Year-Old Woman
Clinical Presentation:
PM: No known comorbidities
Initial Clinical Workup and Diagnosis:
Initial Treatments:
FDA Enforces Partial Hold on Trial of Seclidemstat in MDS/CMML
July 16th 2024Following the report of a serious and unexpected grade 4 adverse effect, a partial clinical hold has been placed on the phase 1 trial evaluating seclidemstat with azacitidine in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Read More